左炔诺孕酮宫内缓释系统与宫腔镜憩室切除术治疗经后点滴出血:一项3年随机试验随访
这项单中心随机试验的3年随访纳入208例剖宫产术后经后点滴出血、MRI确诊憩室深度≥2.0 mm且残余肌层≥2.2 mm、1年内无妊娠计划的女性,比较52 mg左炔诺孕酮宫内缓释系统与宫腔镜憩室切除术。36个月时,左炔诺孕酮宫内缓释系统组98.9%与宫腔镜组51.7%达到点滴出血较基线减少≥50%(相对风险1.91,95%CI 1.56-2.34,P<.001),左炔诺孕酮宫内缓释系统从24个月起优势明显。作者推荐左炔诺孕酮宫内缓释系统作为至少未来1年无生育需求的育龄女性憩室相关点滴出血的一线治疗。
要点
- 36个月时左炔诺孕酮宫内缓释系统组98.9%达到点滴出血减少≥50%,宫腔镜组为51.7%(RR 1.91,95%CI 1.56-2.34,P<.001)。
- 左炔诺孕酮宫内缓释系统组点滴出血持续减少至36个月(Ptrend=0.001),宫腔镜组仅减少至24个月(P=.007)后轻度回升。
- 左炔诺孕酮宫内缓释系统组自6个月起经后点滴出血天数、总出血天数(P<.001)及盆腔痛(P<.010)均更少,差异随时间扩大。
核心结论
- 36个月内,52 mg左炔诺孕酮宫内缓释系统在减少经后点滴出血、盆腔痛和不适方面优于宫腔镜憩室切除术,同时为有症状憩室的女性提供避孕获益。
- 作者推荐左炔诺孕酮宫内缓释系统作为至少未来1年无生育需求的育龄女性憩室相关点滴出血的一线治疗。
研究设计与样本
- 本研究为单中心随机试验的3年随访。
- 纳入剖宫产术后经后点滴出血、磁共振成像确诊憩室深度≥2.0 mm且残余肌层≥2.2 mm、1年内无妊娠计划的女性,随机接受52 mg左炔诺孕酮宫内缓释系统或宫腔镜憩室切除术。
- 共208例女性随机分组(每组104例),左炔诺孕酮宫内缓释系统组93例(89.4%)、宫腔镜憩室切除组89例(85.6%)完成3年随访。
- 主要结局为36个月时点滴出血较基线减少≥50%的女性比例,次要结局包括月经模式、点滴出血不适、慢性盆腔痛及治疗满意度,于18、24、30和36个月评估。
主要发现
- 36个月时,左炔诺孕酮宫内缓释系统组98.9%与宫腔镜组51.7%达到点滴出血减少≥50%(相对风险1.91,95%CI 1.56-2.34,P<.001)。
- 左炔诺孕酮宫内缓释系统组点滴出血至36个月持续减少(Ptrend=0.001),宫腔镜组仅减少至24个月(P=.007)后轻度增加。
- 观察到显著的时间-治疗交互作用(P=.007),左炔诺孕酮宫内缓释系统从24个月起点滴出血减少更优。
- 左炔诺孕酮宫内缓释系统组自6个月起经后点滴出血天数、总出血天数(P<.001)及盆腔痛(P<.010)均更少,差异随时间扩大。
- 随访期间,左炔诺孕酮宫内缓释系统组20例报告激素相关副作用,2例发生部分脱落;宫腔镜组报告5例妊娠(3例非计划、2例计划)。
临床怎么用
- 作者推荐左炔诺孕酮宫内缓释系统作为至少未来1年无生育需求的育龄女性憩室相关点滴出血的一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous findings demonstrated that both the 52-mg levonorgestrel intrauterine system and hysteroscopic niche resection significantly reduced niche-related postmenstrual spotting, with more than 70% of patients achieving ≥50% reduction at 6 months and levonorgestrel intrauterine system showing superior efficacy beyond 9 months. OBJECTIVE: This study evaluates the long-term effectiveness of both treatments in reducing niche-related postmenstrual spotting over 36 months. STUDY DESIGN: This 3-year follow-up stems from a single-center randomized trial. Women experiencing postmenstrual spotting after cesarean delivery, with magnetic resonance imaging-confirmed niche depth ≥2.0 mm and residual myometrium ≥2.2 mm, and without plans to conceive within 1 year, were randomized to receive either the 52-mg levonorgestrel intrauterine system or hysteroscopic niche resection. Main outcome of this long-term follow-up was the proportion of women achieving ≥50% reduction in spotting from baseline at 36 months. Secondary outcomes, including menstrual patterns, spotting discomfort, chronic pelvic pain, and satisfaction with treatment, were assessed at 18, 24, 30, and 36 months. RESULTS: A total of 208 women were randomized (104 in each group), with 93 (89.4%) in the levonorgestrel intrauterine system group and 89 (85.6%) in the hysteroscopic niche resection group completing the 3-year follow-up. At 36 months, 98.9% of women in the levonorgestrel intrauterine system group and 51.7% in the hysteroscopic group achieved a 50% reduction in spotting (relative risk, 1.91 [95% confidence interval, 1.56-2.34]; P<.001). Spotting decreased progressively over time in the levonorgestrel intrauterine system group through 36 months (Ptrend=0.001), whereas the hysteroscopic group showed reduction only until 24 months (P=.007), followed by a slight increase. A significant time-treatment interaction was observed (P=.007), with levonorgestrel intrauterine system demonstrating superior spotting reduction from 24 months onward. Additionally, the levonorgestrel intrauterine system group had fewer postmenstrual spotting days, total bleeding days (P<.001), and less pelvic pain (P<.010) from 6 months onward, with the difference widening over time. During the follow-up, 20 women in the levonorgestrel intrauterine system group reported hormone-related side effects, and 2 experienced partial expulsions. In the hysteroscopic group, 5 pregnancies were reported (3 unintended and 2 planned). CONCLUSION: Over 36 months, the 52-mg levonorgestrel intrauterine system was superior to hysteroscopic niche resection for reducing postmenstrual spotting, pelvic pain, and discomfort, while also offering contraceptive benefits in women with symptomatic niche. We recommend levonorgestrel intrauterine system as a first-line treatment for niche-related spotting in reproductive-age women with no fertility desire for at least the next year.
引用
- Yan L, Zhu C, Xia W, et al. Levonorgestrel intrauterine system vs hysteroscopic niche resection for postmenstrual spotting: a 3-year randomized trial follow-up. Am J Obstet Gynecol. 2025. PMID: 40945810. doi:10.1016/j.ajog.2025.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。